Metronomic 5-fluorouracil, oxaliplatin and irinotecan in colorectal cancer

European Journal of Pharmacology

Volumn 619, Issue 1-3, 2009, Pages 8-14

  Fioravanti, Anna ^a   Canu, Bastianina ^a   Alì, Greta ^a   Orlandi, Paola ^a   Allegrini, Giacomo ^a,c   Di Desidero, Teresa ^a   Emmenegger, Urban ^b   Fontanini, Gabriella ^a   Danesi, Romano ^a   Del Tacca, Mario ^a   Falcone, Alfredo ^a   Bocci, Guido ^a  

^a UNIVERSITY OF PISA   (Italy)

^b DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

^c Nucleo Operativo Igiene e Profilassi Delle Malattie Infettive   (Italy)

Author keywords

5 FU; Angiogenesis; Colon cancer; Combination index; Irinotecan; Metronomic chemotherapy; Oxaliplatin

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; FLUOROURACIL; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; CELL STRAIN HT29; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EXPOSURE; DRUG POTENTIATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; TOXICITY; TUMOR XENOGRAFT; WEIGHT REDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL LINE; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG ADMINISTRATION SCHEDULE; ENDOTHELIAL CELLS; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICROVESSELS; NEOVASCULARIZATION, PATHOLOGIC; ORGANOPLATINUM COMPOUNDS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 69949092611     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.08.020     Document Type: Article

References (31)

1. Albertsson P., Lennernas B., and Norrby K. Low-dose continuous 5-fluorouracil infusion stimulates VEGF-A-mediated angiogenesis. Acta Oncol. 48 (2009) 418-425
2. Allegrini G., Falcone A., Fioravanti A., Barletta M.T., Orlandi P., Loupakis F., Cerri E., Masi G., Di Paolo A., Kerbel R.S., Danesi R., Del Tacca M., and Bocci G. A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients. Br. J. Cancer 98 (2008) 1312-1319
3. Azrak R.G., Cao S., Slocum H.K., Toth K., Durrani F.A., Yin M.B., Pendyala L., Zhang W., McLeod H.L., and Rustum Y.M. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clin. Cancer Res. 10 (2004) 1121-1129
4. Bocci G., Nicolaou K.C., and Kerbel R.S. Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res. 62 (2002) 6938-6943
5. Bocci G., Falcone A., Fioravanti A., Orlandi P., Di Paolo A., Fanelli G., Viacava P., Naccarato A.G., Kerbel R.S., Danesi R., Del Tacca M., and Allegrini G. Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib. Br. J. Cancer 98 (2008) 1619-1629
6. Chou T.C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58 (2006) 621-681
7. Coleman M., Martin P., Ruan J., Furman R., Niesvizky R., Elstrom R., George P., Leonard J., and Kaufmann T. Low-dose metronomic, multidrug therapy with the PEP-C oral combination chemotherapy regimen for mantle cell lymphoma. Leuk. Lymphoma 49 (2008) 447-450
8. Dellapasqua S., Bertolini F., Bagnardi V., Campagnoli E., Scarano E., Torrisi R., Shaked Y., Mancuso P., Goldhirsch A., Rocca A., Pietri E., and Colleoni M. Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. J. Clin. Oncol. 26 (2008) 4899-4905
9. Drevs J., Fakler J., Eisele S., Medinger M., Bing G., Esser N., Marme D., and Unger C. Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy. Anticancer Res. 24 (2004) 1759-1763
10. Dursun B., He Z., Somerset H., Oh D.J., Faubel S., and Edelstein C.L. Caspases and calpain are independent mediators of cisplatin-induced endothelial cell necrosis. Am. J. Physiol. Renal. Physiol. 291 (2006) F578-F587
11. Emmenegger U., Morton G.C., Francia G., Shaked Y., Franco M., Weinerman A., Man S., and Kerbel R.S. Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. Cancer Res. 66 (2006) 1664-1674
12. Fischel J.L., Rostagno P., Formento P., Dubreuil A., Etienne M.C., and Milano G. Ternary combination of irinotecan, fluorouracil-folinic acid and oxaliplatin: results on human colon cancer cell lines. Br. J. Cancer 84 (2001) 579-585
13. Grothey E., and Chu E. The clinical efficacy of FOLFIRI and bevacizumab in combination as first-line therapy of metastatic colorectal cancer. Clin. Colorectal Cancer 6 (2007) 621-624
14. Kerbel R.S., and Kamen B.A. The anti-angiogenic basis of metronomic chemotherapy. Nat. Rev. Cancer 4 (2004) 423-436
15. Klement G., Baruchel S., Rak J., Man S., Clark K., Hicklin D.J., Bohlen P., and Kerbel R.S. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J. Clin. Invest. 105 (2000) R15-R24
16. Klement G., Huang P., Mayer B., Green S.K., Man S., Bohlen P., Hicklin D., and Kerbel R.S. Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. Clin. Cancer Res. 8 (2002) 221-232
17. Laquente B., Lacasa C., Ginesta M.M., Casanovas O., Figueras A., Galan M., Ribas I.G., Germa J.R., Capella G., and Vinals F. Antiangiogenic effect of gemcitabine following metronomic administration in a pancreas cancer model. Mol. Cancer Ther. 7 (2008) 638-647
18. Lin P.C., Chen W.S., Chao T.C., Yang S.H., Tiu C.M., and Liu J.H. Biweekly oxaliplatin plus 1-day infusional fluorouracil/leucovorin followed by metronomic chemotherapy with tegafur/uracil in pretreated metastatic colorectal cancer. Cancer Chemother. Pharmacol. 60 (2007) 351-356
19. Louvet C., Coudray A.M., Tournigand C., Prevost S., Raymond E., de Gramont A., Chazard M., and Gespach C. Synergistic antitumoral activity of combined UFT, folinic acid and oxaliplatin against human colorectal HT29 cell xenografts in athymic nude mice. Anticancer Drugs 11 (2000) 579-582
20. Ma J., and Waxman D.J. Modulation of the antitumor activity of metronomic cyclophosphamide by the angiogenesis inhibitor axitinib. Mol. Cancer. Ther. 7 (2008) 79-89
21. Munoz R., Man S., Shaked Y., Lee C.R., Wong J., Francia G., and Kerbel R.S. Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. Cancer Res. 66 (2006) 3386-3391
22. Ooyama A., Oka T., Zhao H.Y., Yamamoto M., Akiyama S.I., and Fukushima M. Anti-angiogenic effect of 5-fluorouracil-based drugs against human colon cancer xenografts. Cancer Lett. 267 (2008) 26-36
23. Patel M., Agarwal R., and Ardalan B. Effects of oxaliplatin and CPT-11 on cytotoxicity and nucleic acid incorporation of the fluoropyrimidines. J. Cancer Res. Clin. Oncol. 130 (2004) 453-459
24. Petrangolini G., Tortoreto M., Perego P., Carenini N., De Cesare M., Balsari A., Zunino F., and Pratesi G. Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol. Ther. 7 (2008) 596-601
25. Pietras K., and Hanahan D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23 (2005) 939-952
26. Steinbild S., Arends J., Medinger M., Haring B., Frost A., Drevs J., Unger C., Strecker R., Hennig J., and Mross K. Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients-results of a phase II study. Onkologie 30 (2007) 629-635
27. Temmink O.H., Hoebe E.K., van der Born K., Ackland S.P., Fukushima M., and Peters G.J. Mechanism of trifluorothymidine potentiation of oxaliplatin-induced cytotoxicity to colorectal cancer cells. Br. J. Cancer 96 (2007) 231-240
28. Tran J., Master Z., Yu J.L., Rak J., Dumont D.J., and Kerbel R.S. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc. Natl. Acad. Sci. U S A 99 (2002) 4349-4354
29. Vasvari G.P., Dyckhoff G., Kashfi F., Lemke B., Lohr J., Helmke B.M., Schirrmacher V., Plinkert P.K., Beckhove P., and Herold-Mende C.C. Combination of thalidomide and cisplatin in an head and neck squamous cell carcinomas model results in an enhanced antiangiogenic activity in vitro and in vivo. Int. J. Cancer 121 (2007) 1697-1704
30. Wolpin B.M., Meyerhardt J.A., Mamon H.J., and Mayer R.J. Adjuvant treatment of colorectal cancer. CA Cancer J. Clin. 57 (2007) 168-185
31. Yap R., Veliceasa D., Emmenegger U., Kerbel R.S., McKay L.M., Henkin J., and Volpert O.V. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy. Clin. Cancer Res. 11 (2005) 6678-6685